By Michele Maatouk
Date: Tuesday 31 Mar 2026
(Sharecast News) - Shares in Apellis Pharmaceuticals rocketed on Tuesday after it agreed to be bought by Biogen in a $5.6bn deal.
| Currency | US Dollars |
| Share Price | $ 202.19 |
| Change Today | $ 1.57 |
| % Change | 0.78 % |
| 52 Week High | $216.28 |
| 52 Week Low | $126.64 |
| Volume | 596,372 |
| Shares Issued | 146.80m |
| Market Cap | $29,682m |
| RiskGrade | 259 |
| Time | Volume / Share Price |
| 16:00 | 171,226 @ $202.19 |
| 15:59 | 100 @ $202.14 |
| 15:59 | 100 @ $202.10 |
| 15:59 | 250 @ $202.14 |
| 15:59 | 100 @ $202.01 |
You are here: research